Neonatal Fc Receptor: From Immunity to Therapeutics

DSpace/Manakin Repository

Neonatal Fc Receptor: From Immunity to Therapeutics

Citable link to this page


Title: Neonatal Fc Receptor: From Immunity to Therapeutics
Author: Yoshida, Masaru; Qiao, Shuo-Wang; Aveson, Victoria G.; Kuo, Timothy Ting-Chang; Baker, Kristi Dorothy; Lencer, Wayne Isaac; Blumberg, Richard Steven

Note: Order does not necessarily reflect citation order of authors.

Citation: Kuo, Timothy T., Kristi Baker, Masaru Yoshida, Shuo-Wang Qiao, Victoria G. Aveson, Wayne I. Lencer, and Richard S. Blumberg. 2010. Neonatal Fc receptor: from immunity to therapeutics. Journal of Clinical Immunology 30(6): 777-789.
Full Text & Related Files:
Abstract: The neonatal Fc receptor (FcRn), also known as the Brambell receptor and encoded by Fcgrt, is a MHC class I like molecule that functions to protect IgG and albumin from catabolism, mediates transport of IgG across epithelial cells, and is involved in antigen presentation by professional antigen presenting cells. Its function is evident in early life in the transport of IgG from mother to fetus and neonate for passive immunity and later in the development of adaptive immunity and other functions throughout life. The unique ability of this receptor to prolong the half-life of IgG and albumin has guided engineering of novel therapeutics. Here, we aim to summarize the basic understanding of FcRn biology, its functions in various organs, and the therapeutic design of antibody- and albumin-based therapeutics in light of their interactions with FcRn.
Published Version: doi:10.1007/s10875-010-9468-4
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search